Loading...

TORNTPHARM Torrent Pharmaceuticals Ltd Investments/Divestments Announcement

Trrn

TRNT

Torrent Pharmaceuticals Ltd

(TORNTPHARM)

2024 Announcement

Show Summary

Summary

AGM Notice Sent

AGM Announcement

Acquisition Update

52nd AGM Announcement

Acquisition Presentation

Investor Conference Call

Major Acquisition Announced

Commercial Paper Redemption

Commercial Papers Issued

Commercial Paper Redemption

Commercial Papers Issued

ESG Rating Assigned

Share Transfer Notice

Earnings Call Transcript

Compliance Report

Investor Meet Outcome

Management Change

Fundraising Announcement

Management Change

Investor Presentation

Investor Meet Scheduled

Director Cessation

Commercial Papers Issued

Commercial Paper Redemption

Commercial Paper Issue

Credit Rating Update

Management Change

Investor Meet Scheduled

Penalty Disclosure

Investor Meet Notice

Investor Meet Scheduled

Investor Meet Scheduled

Earnings Call Transcript

Analyst Meet Outcome

Investor Presentation

Investor Conference Call

Commercial Paper Issued

Commercial Papers Redemption

Debenture Redemption

IEPF Shares Transfer

Brand Acquisition

Tax Penalty Imposed

FDA Inspection Update

Earnings Call Update

Conference Call Update

Q2 Results Presentation

Credit Rating Reaffirmed

Regulatory Penalty

Regulatory Penalty Notice

Investor Call Scheduled

New Subsidiary Formation

Quality Test Claims Refuted

Investor Roadshows

FDA Inspection Update

Tax Penalty Imposed

USFDA Inspection Result

Tax Penalty Issued

Tax Penalty Notice

GST Penalty Notification

Credit Rating Reaffirmed

Clarification Issued

Management Change

Earnings Call Transcript

Conference Call Outcome

Management Change

Financial Results Presentation

Teleconference Announcement

Newspaper Advertisement

Demand Notice from NPPA

Inspection Observations

Patent Licensing Agreement

Earnings Call Transcript

Sharing Transfer to IEPF

Resignation of Director

Analyst/Investor Meet Outcome

Financial Results & Dividen...

Financial Results and Manag...

Board Changes & Financial R...

Financial Results Presentation

Compliance Report Submission

Financial Announcement

Tax Penalty Communication

Tax Penalty Order

Compliance Certificate

Compliance Certificate

Cessation of Directors

Retirement Announcement

Director Resignations

USFDA EIR Received

Penalty Imposed

Management Change

Investor Conferences

Investor Conferences

Investor Conferences

Investor Meetings

Audio Recording Release

Presentation to Analysts

Investment Settlement

Conference Call with Investors

Acquisition of TIPL equity ...

Penalty Imposed

Wholly Owned Subsidiary Inc...

Penalty Imposed

Regulatory Action

Partial Redemption

US FDA Inspection

Shares Transfer to IEPF

Licensing Agreement

Credit Rating Affirmation

Dispatch of Postal Ballot N...

Presentation to Analysts

Credit Rating Announcement

Equity, Debt, VC, Private E...

Post-Market Surveillance

Conference Call Transcript

Financial Results

Appointments/Resignations

Equity, Debt, VC, Private E...

Financial Statements

Conference Call

Investor Meetings

Financial Statements

Successful Inspection

Financial Results

Financial Results Presentation

Equity Offerings

Observations Received

Appointments/Resignations

Merger of Equals

Post Earnings Conference Call

External Links:

Data:

Torrent Pharmaceuticals entered into a non-exclusive patent licensing agreement with Takeda Pharmaceuticals to commercialize Vonoprazan in India for treating Gastroesophageal Reflux Disease (GERD). The Indian market for GERD treatments is valued at INR 8,064 crore, growing at 8% CAGR over the last 4 years.

AI Assistant

Torrent Pharmaceuticals Ltd

2024

Announcement

Find Answers

Ask about any part of the document to get insights, explanations, or key details.